Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Vishal Unadkat, Shishir Rohit, Paranjay Parikh, Kaushal Patel, Vinod Sanna & Sanjay Singh. (2022) Identification of 1,2,4-Oxadiazoles-Based Novel EGFR Inhibitors: Molecular Dynamics Simulation-Guided Identification and in vitro ADME Studies. OncoTargets and Therapy 15, pages 479-495.
Read now
Read now
Swati Singh, Manika Awasthi, Veda P. Pandey & Upendra N. Dwivedi. (2017) Lipoxygenase directed anti-inflammatory and anti-cancerous secondary metabolites: ADMET-based screening, molecular docking and dynamics simulation. Journal of Biomolecular Structure and Dynamics 35:3, pages 657-668.
Read now
Read now
Victor A. Voicu, Andrei Valentin Medvedovici, Koichi Sakurada, Hikoto Ohta, Flavian Ștefan Rădulescu & Dalia Simona Miron. (2016) The forgotten or underestimated relevance of biopharmaceutical-based assessments for the oral absorption studies of oxime reactivators. Expert Opinion on Drug Metabolism & Toxicology 12:7, pages 743-752.
Read now
Read now
Matthew Segall. (2014) Advances in multiparameter optimization methods for de novo drug design. Expert Opinion on Drug Discovery 9:7, pages 803-817.
Read now
Read now
Luis G Valerio$suffix/text()$suffix/text(), Chihae Yang, Kirk B Arvidson & Naomi L Kruhlak. (2010) A structural feature-based computational approach for toxicology predictions. Expert Opinion on Drug Metabolism & Toxicology 6:4, pages 505-518.
Read now
Read now
Tingjun Hou & Junmei Wang. (2008) Structure – ADME relationship: still a long way to go?. Expert Opinion on Drug Metabolism & Toxicology 4:6, pages 759-770.
Read now
Read now
John C Dearden. (2007) In silico prediction of ADMET properties: how far have we come?. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 635-639.
Read now
Read now
Articles from other publishers (46)
Rayenne Redjemia, Malika Berredjem, Ali Dekir, Malika Ibrahim-Ouali, Mohamed Aissaoui, Sofiane Bouacida, Abdeslem Bouzina & Rania Bahadi. (2023) A convenient synthesis, in silico study and crystal structure of novel sulfamidophosphonates: Interaction with SARS-CoV-2. Journal of Molecular Structure 1275, pages 134602.
Crossref
Crossref
Brandon G Santiago, Stephen H Eisennagel, Gregory E Peckham, Amanda M Liebhardt, Chad L Alburn, Theresa J Roethke, Michael A Reilly, Jens R Sydor & Molly Z Karlinsey. (2023)
Perspective on high-throughput bioanalysis to support
in vitro
assays in early drug discovery
. Bioanalysis 15:3, pages 177-191.
Crossref
Crossref
Andrey A. Toropov, Maria Raskova, Ivan RaskaJr.Jr. & Alla P. Toropova. 2023. QSPR/QSAR Analysis Using SMILES and Quasi-SMILES. QSPR/QSAR Analysis Using SMILES and Quasi-SMILES
3
24
.
Abdeslem Bouzina, Malika Berredjem, Sofiane Bouacida, Khaldoun Bachari, Christelle Marminon, Marc Le Borgne, Zouhair Bouaziz & Yousra Ouafa Bouone. (2022) Synthesis, in silico study (DFT, ADMET) and crystal structure of novel sulfamoyloxy-oxazolidinones: Interaction with SARS-CoV-2. Journal of Molecular Structure 1257, pages 132579.
Crossref
Crossref
J Priya & D Madheswari. (2022) Biomolecular docking interactions, cytotoxicity and antioxidant property evaluations with novel Mn(II), Ni(II), Cd(II) and Pb(II) Schiff base ligand complexes: Synthesis and characterization. Journal of Biosciences 47:2.
Crossref
Crossref
Christoph Grebner, Hans Matter & Gerhard Hessler. 2022. Artificial Intelligence in Drug Design. Artificial Intelligence in Drug Design
349
382
.
Muhammad SarfrazAbdul RaufPaul KellerAshfaq Mahmood Qureshi. (2021)
N
,
N
′-dialkyl-2-thiobarbituric acid based sulfonamides as potential SARS-CoV-2 main protease inhibitors
. Canadian Journal of Chemistry 99:3, pages 330-345.
Crossref
Crossref
Johan WernevikFredrik BergströmAnna NovénJohan HultheLinda FredlundDan AddisonJan HolmgrenPer-Erik StrömstedtErika RehnströmThomas Lundbäck. (2020) A Fully Integrated Assay Panel for Early Drug Metabolism and Pharmacokinetics Profiling. ASSAY and Drug Development Technologies 18:4, pages 157-179.
Crossref
Crossref
Matthew Segall, Tamsin Mansley, Peter Hunt & Edmund Champness. (2019) Capturing and applying knowledge to guide compound optimisation. Drug Discovery Today 24:5, pages 1074-1080.
Crossref
Crossref
Zhuyifan Ye, Yilong Yang, Xiaoshan Li, Dongsheng Cao & Defang Ouyang. (2018) An Integrated Transfer Learning and Multitask Learning Approach for Pharmacokinetic Parameter Prediction. Molecular Pharmaceutics 16:2, pages 533-541.
Crossref
Crossref
Jakub Kollar & Vladimir Frecer. (2018) Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations. Journal of Molecular Graphics and Modelling 85, pages 97-110.
Crossref
Crossref
Aminael Sánchez-Rodríguez, Yunierkis Pérez-Castillo, Stephan C. Schürer, Orazio Nicolotti, Giuseppe Felice Mangiatordi, Fernanda Borges, M. Natalia D.S. Cordeiro, Eduardo Tejera, José L. Medina-Franco & Maykel Cruz-Monteagudo. (2017) From flamingo dance to (desirable) drug discovery: a nature-inspired approach. Drug Discovery Today 22:10, pages 1489-1502.
Crossref
Crossref
M.P. Gleeson & D. Montanari. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
64
93
.
Jin Han, Silje Henriksen, Kristin G. Nørsett, Eirik Sundby & Bård Helge Hoff. (2016) Balancing potency, metabolic stability and permeability in pyrrolopyrimidine-based EGFR inhibitors. European Journal of Medicinal Chemistry 124, pages 583-607.
Crossref
Crossref
Matthew D. SegallIskander YusofEdmund J. Champness. (2016) Avoiding Missed Opportunities by Analyzing the Sensitivity of Our Decisions. Journal of Medicinal Chemistry 59:9, pages 4267-4277.
Crossref
Crossref
Matthew D. Segall & Peter Hunt. 2016. Lead Generation. Lead Generation
425
450
.
Swati Singh, Tamal Das, Manika Awasthi, Veda P. Pandey, Brijesh Pandey & Upendra N. Dwivedi. (2016) DNA topoisomerase-directed anticancerous alkaloids: ADMET-based screening, molecular docking, and dynamics simulation. Biotechnology and Applied Biochemistry 63:1, pages 125-137.
Crossref
Crossref
Matthew Segall. 2015. New Horizons in Predictive Drug Metabolism and Pharmacokinetics. New Horizons in Predictive Drug Metabolism and Pharmacokinetics
227
246
.
Matthew Segall, Ed Champness, Chris Leeding, James Chisholm, Peter Hunt, Alex Elliott, Hector Garcia-Martinez, Nick Foster & Samuel Dowling. (2015) Breaking free from chemical spreadsheets. Drug Discovery Today 20:9, pages 1093-1103.
Crossref
Crossref
Matthew D. Segall & Edmund J. Champness. (2015) The challenges of making decisions using uncertain data. Journal of Computer-Aided Molecular Design 29:9, pages 809-816.
Crossref
Crossref
Susanne Winiwarter, Brian Middleton, Barry Jones, Paul Courtney, Bo Lindmark, Ken M. Page, Alan Clark & Claire Landqvist. (2015) Time dependent analysis of assay comparability: a novel approach to understand intra- and inter-site variability over time. Journal of Computer-Aided Molecular Design 29:9, pages 795-807.
Crossref
Crossref
Santiago Vilar, Nicholas P. Tatonetti & George Hripcsak. (2015) 3D Pharmacophoric Similarity improves Multi Adverse Drug Event Identification in Pharmacovigilance. Scientific Reports 5:1.
Crossref
Crossref
Upendra N. DwivediSameeksha TiwariPriyanka SinghSwati SinghManika AwasthiVeda P. Pandey. (2015)
Treponema pallidum
Putative Novel Drug Target Identification and Validation: Rethinking Syphilis Therapeutics with Plant-Derived Terpenoids
. OMICS: A Journal of Integrative Biology 19:2, pages 104-114.
Crossref
Crossref
Sarfaraz K. Niazi. 2014. Handbook of Bioequivalence Testing. Handbook of Bioequivalence Testing
756
787
.
Matthew D. Segall & Chris Barber. (2014) Addressing toxicity risk when designing and selecting compounds in early drug discovery. Drug Discovery Today 19:5, pages 688-693.
Crossref
Crossref
George Papadatos, Valerie J. Gillet, Christopher N. Luscombe, Iain M. McLay, Stephen D. Pickett & Peter Willett. 2013. Chemoinformatics for Drug Discovery. Chemoinformatics for Drug Discovery
179
204
.
Hans Matter, Stefan Güssregen, Friedemann Schmidt, Gerhard Hessler, Thorsten Naumann & Karl‐Heinz Baringhaus. 2013. Chemoinformatics for Drug Discovery. Chemoinformatics for Drug Discovery
205
243
.
David J. Wood, Lars Carlsson, Martin Eklund, Ulf Norinder & Jonna Stålring. (2013) QSAR with experimental and predictive distributions: an information theoretic approach for assessing model quality. Journal of Computer-Aided Molecular Design 27:3, pages 203-219.
Crossref
Crossref
Alexander V. LyubimovJochem Alsenz. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
70
.
Rajinder Bhardwaj & Gamini Chandrasena. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
15
28
.
Matthew SegallAndrew Chadwick. (2011) The risks of subconscious biases in drug-discovery decision making. Future Medicinal Chemistry 3:7, pages 771-774.
Crossref
Crossref
Natalia A. Penner, Ginny Ho, Ana Bercovici, Swapan K. Chowdhury & Kevin B. Alton. (2010) Identification of Two Novel Metabolites of SCH 486757, a Nociceptin/Orphanin FQ Peptide Receptor Agonist, in Humans. Drug Metabolism and Disposition 38:11, pages 2067-2074.
Crossref
Crossref
Andrew T. Chadwick & Matthew D. Segall. (2010) Overcoming psychological barriers to good discovery decisions. Drug Discovery Today 15:13-14, pages 561-569.
Crossref
Crossref
William J. Egan. 2010. Drug Design. Drug Design
165
178
.
Maykel Cruz-Monteagudo, Hai PhamThe, M. Natalia D. S. Cordeiro & Fernanda Borges. (2010) Prioritizing Hits with Appropriate Trade-Offs Between HIV-1 Reverse Transcriptase Inhibitory Efficacy and MT4 Blood Cells Toxicity Through Desirability-Based Multiobjective Optimization and Ranking. Molecular Informatics 29:4, pages 303-321.
Crossref
Crossref
Gisbert Schneider & Andreas Schüller. 2010. Ligand-Macromolecular Interactions in Drug Discovery. Ligand-Macromolecular Interactions in Drug Discovery
135
147
.
Matthew Segall, Edmund Champness, Olga Obrezanova & Chris Leeding. (2009) Beyond Profiling: Using ADMET Models to Guide Decisions. Chemistry & Biodiversity 6:11, pages 2144-2151.
Crossref
Crossref
Cheng Chang, David B Duignan, Kjell D Johnson, Pil H Lee, George S Cowan, Eric M Gifford, Charles J Stankovic, Christopher S Lepsy & Chad L Stoner. (2009) The Development and Validation of a Computational Model to Predict Rat Liver Microsomal Clearance. Journal of Pharmaceutical Sciences 98:8, pages 2857-2867.
Crossref
Crossref
Natalia Penner, Lewis J. Klunk & Chandra Prakash. (2009) Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharmaceutics & Drug Disposition 30:4, pages 185-203.
Crossref
Crossref
Chandra Prakash & Alfin D. N. Vaz. 2008. Nuclear Receptors in Drug Metabolism. Nuclear Receptors in Drug Metabolism
1
41
.
Igor V. Tetko & Tudor I. Oprea. 2008. Chemoinformatics Approaches to Virtual Screening. Chemoinformatics Approaches to Virtual Screening
240
267
.
Valerie J Gillet. (2008) New directions in library design and analysis. Current Opinion in Chemical Biology 12:3, pages 372-378.
Crossref
Crossref
John C Dearden. (2007)
In silico
prediction of ADMET properties: how far have we come?
. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 635-639.
Crossref
Crossref
Olga Obrezanova, Gábor Csányi, Joelle M. R. Gola & Matthew D. Segall. (2007) Gaussian Processes: A Method for Automatic QSAR Modeling of ADME Properties. Journal of Chemical Information and Modeling 47:5, pages 1847-1857.
Crossref
Crossref
William J. Egan. 2007. Annual Reports in Medicinal Chemistry Volume 42. Annual Reports in Medicinal Chemistry Volume 42
449
467
.
Joelle Gola, Olga Obrezanova, Ed Champness & Matthew Segall. (2006) ADMET Property Prediction: The State of the Art and Current Challenges. QSAR & Combinatorial Science 25:12, pages 1172-1180.
Crossref
Crossref